Alkem Laboratories logo

ALKEM - Alkem Laboratories Share Price

₹2751.75 6.2  0.2%

Last Trade - 13/04/21

Large Cap
Market Cap £3.19bn
Enterprise Value £3.17bn
Revenue £847.7m
Position in Universe 120th / 3106
Unlock ALKEM Revenue
Relative Strength (%)
1m +3.48%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -12.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
37,411 50,479 58,525 64,312 73,572 83,444 89,601 100,626 +17.4%
+4.7 +60.5 +21.6 -29.8 +21.0 +48.7 +45.0 -3.42
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 December 2020, AlkemLaboratories Ltd revenues increased 6% to RS66.84B. Netincome increased 43% to RS13.45B. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Net income benefitedfrom Other expenses decrease of 16% to RS12.54B (expense),Other income increase from RS767.5M to RS1.75B (income),Finance costs decrease of 5% to RS482.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ALKEM
Graphical History


ALKEM Revenue Unlock ALKEM Revenue

Net Income

ALKEM Net Income Unlock ALKEM Revenue

Normalised EPS

ALKEM Normalised EPS Unlock ALKEM Revenue

PE Ratio Range

ALKEM PE Ratio Range Unlock ALKEM Revenue

Dividend Yield Range

ALKEM Dividend Yield Range Unlock ALKEM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ALKEM EPS Forecasts Unlock ALKEM Revenue
Profile Summary

Alkem Laboratories Limited is a pharmaceutical company. The Company is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates through two segments: pharmaceutical and investing. The Company produces generics, generic drugs, active pharmaceutical ingredients (APIs) and neutraceuticals, which it markets in India and approximately 50 countries internationally, primarily the United States. The Company offers various products, such as CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, among others. The Company has approximately 16 manufacturing facilities, of which 14 manufacturing facilities are at geographically diversified locations in India and two in the United States.

Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated August 8, 1973
Public Since December 23, 2015
No. of Shareholders: 75,863
No. of Employees: 14,331
Sector Healthcare
Industry Pharmaceuticals
Exchange National Stock Exchange of India
Shares in Issue 119,550,000
Free Float (0.0%)
Eligible for
ALKEM Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ALKEM
Upcoming Events for ALKEM
Wednesday 18th August, 2021 Estimate
Alkem Laboratories Ltd Annual Shareholders Meeting
Frequently Asked Questions for Alkem Laboratories
What is the Alkem Laboratories share price?

As of 13/04/21, shares in Alkem Laboratories are trading at ₹2751.75, giving the company a market capitalisation of ¬£3.19bn. This share price information is delayed by 15 minutes.

How has the Alkem Laboratories share price performed this year?

Shares in Alkem Laboratories are currently trading at ₹2751.75 and the price has moved by 2.15% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Alkem Laboratories price has moved by -35.76% over the past year.

What are the analyst and broker recommendations for Alkem Laboratories?

Of the analysts with advisory recommendations for Alkem Laboratories, there are there are currently 9 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Alkem Laboratories is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Alkem Laboratories next release its financial results?

Alkem Laboratories is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Alkem Laboratories dividend yield?

The Alkem Laboratories dividend yield is 1.02% based on the trailing twelve month period.

Does Alkem Laboratories pay a dividend?

Last year, Alkem Laboratories paid a total dividend of 28, and it currently has a trailing dividend yield of 1.02%. Looking ahead, Alkem Laboratories has not announced an ex-dividend date yet.

When does Alkem Laboratories next pay dividends?

Alkem Laboratories has yet to annouce their ex-dividend date. The historic dividend yield on Alkem Laboratories shares is currently 1.02%.

How do I buy Alkem Laboratories shares?

To buy shares in Alkem Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Alkem Laboratories?

Shares in Alkem Laboratories are currently trading at ₹2751.75, giving the company a market capitalisation of ¬£3.19bn.

Where are Alkem Laboratories shares listed? Where are Alkem Laboratories shares listed?

Here are the trading details for Alkem Laboratories:

Country of listing: India
Exchange: NSI
Ticker Symbol: ALKEM
What kind of share is Alkem Laboratories?

Based on an overall assessment of its quality, value and momentum, Alkem Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Alkem Laboratories share price forecast 2021?

Shares in Alkem Laboratories are currently priced at ₹2751.75. At that level they are trading at 22.36% discount to the analyst consensus target price of 0.00.

Analysts covering Alkem Laboratories currently have a consensus Earnings Per Share (EPS) forecast of 136.885 for the next financial year.

How can I tell whether the Alkem Laboratories share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alkem Laboratories. Over the past six months, the relative strength of its shares against the market has been -16.23%. At the current price of ₹2751.75, shares in Alkem Laboratories are trading at -0.86% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Alkem Laboratories PE Ratio?

The Alkem Laboratories PE ratio based on its reported earnings over the past 12 months is 21.45. The shares are currently trading at ₹2751.75.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Alkem Laboratories?

Alkem Laboratories's management team is headed by:

Basudeo Singh - NEC
Arun Purwar - IND
Sudha Ravi - IND
Rajesh Dubey - CFO
Girish Jain - CEX
Manish Narang - SVP
Rajbir Sandhu - SVP
Amit Ghare - CEX
Mukesh Tiwary - VPR
K. Prakash - VPR
Satyavan Manikani - VPR
Ambrish Srivastava - VPR
Venkatesh S. - CEX
Dheeraj Sharma - IND
Narendra Aneja - IND
Who are the major shareholders of Alkem Laboratories?

Here are the top five shareholders of Alkem Laboratories based on the size of their shareholding:

Singh (Sarandhar) Individual Investor
Percentage owned: 21.15% (25.3m shares)
Singh (Basudeo Narain) Individual Investor
Percentage owned: 7.24% (8.66m shares)
Singh (Mritunjay Kumar) Individual Investor
Percentage owned: 6.38% (7.63m shares)
Singh (Dhananjay Kumar) Individual Investor
Percentage owned: 6.24% (7.47m shares)
Sinha (Jayanti) Individual Investor
Percentage owned: 5.97% (7.14m shares)
Similar to ALKEM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.